Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972875 · ClinicalTrials.gov registry record · Phase 2
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
A Phase 2 study of Androgen Deprivation Therapy and Prostate CA, sponsored by University of Vermont.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06972875: Recruiting Phase 2 study of Androgen Deprivation Therapy and Prostate CA, sponsored by University of Vermont.
NCT06972875 is a Phase 2 study of Androgen Deprivation Therapy and Prostate CA that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 32 participants, below the 46-participant average among 5 other Androgen Deprivation Therapy trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06972875, a Phase 2 study of Androgen Deprivation Therapy and Prostate CA, is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.
Primary Outcome
Assess the effect of fezolinetant 45 mg daily on the 7-day period participant-reported Hot Flash Score (HFS) at 4 weeks relative to baseline. The HFS sums the number of hot flashes multiplied by the intensity of each hot flash to estimate the overall hot flash burden during a 24 hour period, averaged over a 7 day period.
Conditions Studied
Interventions
- DRUG Fezolinetant
Study Locations (1)
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT06972875 shows while recruiting
NCT06972875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 46-participant average among 5 other Androgen Deprivation Therapy trials with a reported enrollment target (30% lower).
The record links to 2 conditions, with Androgen Deprivation Therapy appearing as the primary indexed condition, and to 1 intervention - of which Fezolinetant is the first listed.
NCT06972875 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT06972875 about?
NCT06972875 is a clinical study titled "Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer". This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testin...
What is the current status of trial NCT06972875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-18. Estimated completion is 2027-02.
What conditions does trial NCT06972875 study?
This clinical trial studies the following conditions: Androgen Deprivation Therapy, Prostate CA.
What interventions are being tested in trial NCT06972875?
The interventions under investigation include: Fezolinetant (DRUG).
Who is sponsoring clinical trial NCT06972875?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972875 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgen Deprivation Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
RECRUITING · NA
-
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
RECRUITING · NA
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
RECRUITING · Phase 1
-
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI